BCG-induced cytokine release in bladder cancer cells is regulated by Ca2+ signaling

Mol Oncol. 2019 Feb;13(2):202-211. doi: 10.1002/1878-0261.12397. Epub 2018 Dec 13.

Abstract

Bacillus Calmette-Guérin (BCG) is widely used in the clinic to effectively treat superficial urinary bladder cancer. However, a significant proportion of patients who fail to respond to BCG risk cystectomy or death. Though more than 3 million cancer treatments with BCG occur annually, surprisingly little is known about the initial signaling cascades activated by BCG. Here, we report that BCG induces a rapid intracellular Ca2+ (calcium ion) signal in bladder cancer cells that is essential for activating the transcription factor nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and for synthesizing and secreting proinflammatory cytokines, including interleukin 8 (IL-8). A similar Ca2+ response was observed when cells were exposed to the supernatant of BCG. Studying cellular molecular mechanisms involved in the BCG signaling event, we found pivotal roles for phospholipase C and the Toll-like receptor 4. Further assessment revealed that this signaling pathway induces synthesis of IL-8, whereas exocytosis appeared to be controlled by global Ca2+ signaling. These results shed new light on the molecular mechanisms underlying BCG treatment of bladder cancer, which can help in improving therapeutic efficacy and reducing adverse side effects.

Keywords: BCG; TLR4; calcium signaling; urinary bladder cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Calcium / metabolism
  • Calcium Signaling*
  • Cell Line, Tumor
  • Cytokines / metabolism*
  • Cytosol / metabolism
  • Humans
  • Interleukin-8 / metabolism
  • Mycobacterium bovis / metabolism*
  • NF-kappa B / metabolism
  • Toll-Like Receptor 4 / metabolism
  • Urinary Bladder Neoplasms / metabolism*

Substances

  • CXCL8 protein, human
  • Cytokines
  • Interleukin-8
  • NF-kappa B
  • TLR4 protein, human
  • Toll-Like Receptor 4
  • Calcium